Reference
1. Pustisek N, Lipozencić J, Ljubojević S. Tacrolimus ointment: a new therapy for atopic dermatitis–review of the literature. Acta Dermatovenerol Croat. 2002;10(1):25-32.
2. Beck LA. The efficacy and safety of tacrolimus ointment: a clinical review. J Am Acad Dermatol. 2005;53(2 Suppl 2):S165-170.
3. Goretzki A, Lin YJ, Schülke S. Immune metabolism in allergies, does it matter?-A review of immune metabolic basics and adaptations associated with the activation of innate immune cells in allergy.Allergy. 2021;76(11):3314-3331.
4. Jiménez M, Cervantes-García D, Córdova-Dávalos LE, et al. Responses of Mast Cells to Pathogens: Beneficial and Detrimental Roles.Front Immunol. 2021;12:685865.
5. Trier AM, Kim BS. Structural insights into MRGPRX2: a new vision of itch and allergy. J Allergy Clin Immunol. 2022.
6. Voss M, Kotrba J, Gaffal E, et al. Mast Cells in the Skin: Defenders of Integrity or Offenders in Inflammation? Int J Mol Sci.2021;22(9).
7. Samukawa K, Izumi Y, Shiota M, et al. Red ginseng inhibits scratching behavior associated with atopic dermatitis in experimental animal models. J Pharmacol Sci. 2012;118(3):391-400.
8. Pereira U, Boulais N, Lebonvallet N, et al. Mechanisms of the sensory effects of tacrolimus on the skin. Br J Dermatol.2010;163(1):70-77.
9. Murota H, El-latif MA, Tamura T, et al. Olopatadine hydrochloride decreases tissue interleukin-31 levels in an atopic dermatitis mouse model. Acta Derm Venereol. 2014;94(1):78-79.
10. Cury Martins J, Martins C, Aoki V, et al. Topical tacrolimus for atopic dermatitis. Cochrane Database Syst Rev. 2015(7):CD009864.
11. Ashcroft DM, Dimmock P, Garside R, et al. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ.2005;330(7490):516.
12. McNeil BD, Pundir P, Meeker S, et al. Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions.Nature. 2015;519(7542):237-241.
13. Meixiong J, Anderson M, Limjunyawong N, et al. Activation of Mast-Cell-Expressed Mas-Related G-Protein-Coupled Receptors Drives Non-histaminergic Itch. Immunity. 2019;50(5):1163-1171 e1165.
14. Subramanian H, Gupta K, Ali H. Roles of Mas-related G protein-coupled receptor X2 on mast cell-mediated host defense, pseudoallergic drug reactions, and chronic inflammatory diseases.J Allergy Clin Immunol. 2016;138(3):700-710.
15. Arifuzzaman M, Mobley YR, Choi HW, et al. MRGPR-mediated activation of local mast cells clears cutaneous bacterial infection and protects against reinfection. Sci Adv. 2019;5(1):eaav0216.
16. Meixiong J, Anderson M, Limjunyawong N, et al. Activation of Mast-Cell-Expressed Mas-Related G-Protein-Coupled Receptors Drives Non-histaminergic Itch. Immunity. 2019;50(5):1163-1171.e1165.
17. Ogasawara H, Noguchi M. Therapeutic Potential of MRGPRX2 Inhibitors on Mast Cells. Cells. 2021;10(11).
18. Cao C, Kang HJ, Singh I, et al. Structure, function and pharmacology of human itch GPCRs. Nature. 2021;600(7887):170-175.
19. Liu R, Che D, Zhao T, et al. MRGPRX2 is essential for sinomenine hydrochloride induced anaphylactoid reactions. Biochem Pharmacol.2017;146:214-223.
20. Cañadas O, Sáenz A, Orellana G, et al. Equilibrium studies of a fluorescent tacrolimus binding to surfactant protein A. Anal Biochem. 2005;340(1):57-65.
21. Ständer S, Ständer H, Seeliger S, et al. Topical pimecrolimus and tacrolimus transiently induce neuropeptide release and mast cell degranulation in murine skin. Br J Dermatol.2007;156(5):1020-1026.
22. Ray P, Torck A, Quigley L, et al. Comparative transcriptome profiling of the human and mouse dorsal root ganglia: an RNA-seq-based resource for pain and sensory neuroscience research. Pain.2018;159(7):1325-1345.
23. McNeil BD. Minireview: Mas-related G protein-coupled receptor X2 activation by therapeutic drugs. Neuroscience Letters. 2021;751.
24. Roy S, Chompunud Na Ayudhya C, Thapaliya M, et al. Multifaceted MRGPRX2: New insight into the role of mast cells in health and disease.J Allergy Clin Immunol. 2021;148(2):293-308.
25. Shtessel M, Limjunyawong N, Oliver ET, et al. MRGPRX2 Activation Causes Increased Skin Reactivity in Patients with Chronic Spontaneous Urticaria. J Invest Dermatol. 2021;141(3):678-681.e672.
26. Ohtsuki M, Morimoto H, Nakagawa H. Tacrolimus ointment for the treatment of adult and pediatric atopic dermatitis: Review on safety and benefits. J Dermatol. 2018;45(8):936-942.
27. Takeuchi S, Saeki H, Tokunaga S, et al. A randomized, open-label, multicenter trial of topical tacrolimus for the treatment of pruritis in patients with atopic dermatitis. Ann Dermatol.2012;24(2):144-150.
28. Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta. 2010;1802(4):396-405.
29. Gilfillan AM, Tkaczyk C. Integrated signalling pathways for mast-cell activation. Nat Rev Immunol. 2006;6(3):218-230.
30. Zelová H, Hošek J. TNF-α signalling and inflammation: interactions between old acquaintances. Inflamm Res. 2013;62(7):641-651.
31. Doszhan A, Bektayeva R, Imanbayeva N, et al. [THE ROLE OF INTERLEUKIN 8 / CXCL8 IN THE IMMUNOPATHOGENESIS AND CARCINOGENESIS OF INFLAMMATORY BOWEL DISEASES (REVIEW)]. Georgian Med News.2019(296):150-153.
32. Choi JE, Di Nardo A. Skin neurogenic inflammation. Semin Immunopathol. 2018;40(3):249-259.
33. Nakahara T, Morimoto H, Murakami N, et al. Mechanistic insights into topical tacrolimus for the treatment of atopic dermatitis. Pediatr Allergy Immunol. 2018;29(3):233-238.
34. Azimi E, Reddy VB, Shade KC, et al. Dual action of neurokinin-1 antagonists on Mas-related GPCRs. JCI Insight. 2016;1(16):e89362.
35. Thapaliya M, Chompunud Na Ayudhya C, Amponnawarat A, et al. Mast Cell-Specific MRGPRX2: a Key Modulator of Neuro-Immune Interaction in Allergic Diseases. Curr Allergy Asthma Rep. 2021;21(1):3.
36. Kim HO, Lee CH, Ahn HK, et al. Effects of tacrolimus ointment on the expression of substance P, nerve growth factor, and neurotrophin-3 in atopic dermatitis. Int J Dermatol. 2009;48(4):431-438.
37. Corbière A, Loste A, Gaudenzio N. MRGPRX2 sensing of cationic compounds-A bridge between nociception and skin diseases? Exp Dermatol. 2021;30(2):193-200.